[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100488464":3},{"organization":4,"armGroups":7,"interventions":19,"overallOfficials":24,"centralContacts":29,"locations":35,"responsibleParty":57,"collaborators":24,"id":60,"slug":61,"hasResults":62,"nctId":63,"briefTitle":64,"officialTitle":65,"acronym":24,"eligibilityCriteria":66,"healthyVolunteers":62,"sex":67,"minAge":68,"maxAge":24,"enrollmentInfo":69,"targetDuration":24,"studyType":72,"phases":73,"briefSummary":75,"conditions":76,"keywords":24,"overallStatus":38,"whyStopped":24,"lastUpdateSubmitDate":79,"lastUpdatePostDateStruct":80,"startDateStruct":83,"completionDateStruct":85,"leadSponsor":87,"locationsCount":88},{"fullName":5,"class":6},"Tanta University","OTHER",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"Pregabalin group","ACTIVE_COMPARATOR","Patients will receive pregabalin capsules (75 mg) every 12 h for 24 hours by nasogastric tube.",[13],"Drug: Pregabalin",{"label":15,"type":10,"description":16,"interventionNames":17},"Dexmedetomidine group","Patients will receive a bolus dose of 0.4 μg\u002Fkg dexmedetomidine (over a period of 10 to 20 min) followed by an infusion of 0.2 to 0.7 μg\u002Fh.",[18],"Drug: Dexmedetomidine",[20,25],{"type":21,"name":22,"description":11,"armGroupLabels":23,"otherNames":24},"DRUG","Pregabalin",[9],null,{"type":21,"name":26,"description":27,"armGroupLabels":28,"otherNames":24},"Dexmedetomidine","Patients will receive a bolus dose of 0.4 μg\u002Fkg dexmedetomidine (over a period of 10 to 20 min)",[15],[30],{"name":31,"role":32,"phone":33,"phoneExt":24,"email":34},"Islam Morsy, MD","CONTACT","00201093387374","eslam.morsy@med.tanta.edu.eg",[36],{"facility":37,"status":38,"city":39,"state":40,"zip":24,"country":41,"countryCode":42,"cosmosGeoPoint":43,"geoPoint":48,"contacts":49},"Islam Morsy","RECRUITING","Tanta","El-Gharbia Governorate","Egypt","EG",{"type":44,"coordinates":45},"Point",[46,47],31.00192,30.78847,{"lat":47,"lon":46},[50,52,55],{"name":31,"role":32,"phone":33,"phoneExt":51,"email":34},"139",{"name":53,"role":54,"phone":24,"phoneExt":24,"email":24},"Mohammed S El Sharkawy, MD","SUB_INVESTIGATOR",{"name":56,"role":54,"phone":24,"phoneExt":24,"email":24},"Hussein G Almawardy, MD",{"type":58,"investigatorFullName":37,"investigatorTitle":59,"investigatorAffiliation":5,"oldNameTitle":24,"oldOrganization":24},"PRINCIPAL_INVESTIGATOR","Lecturer of Anesthesiology, Surgical Intensive Care and Pain Medicine","100488464","phase-4-pregabalin-versus-dexmedetomidine-for-delirium-treatment-after-coronary-artery-bypass-grafting-100488464",false,"NCT05640453","Pregabalin Versus Dexmedetomidine for Delirium Treatment After Coronary Artery Bypass Grafting","Pregabalin Versus Dexmedetomidine for Delirium Treatment After Coronary Artery Bypass Grafting: A Randomized Double-Blind Trial","Inclusion Criteria:\n\n* CABG patients ≥ 65 years of age both genders American Society of Anesthesiologists (ASA) physical status classification II or III planned for fast track developed postoperative delirium (POD).\n\nExclusion Criteria:\n\n* Patients who had history of psychiatric diseases; inability to communicate;\n* previous history of POD; preoperative sick sinus syndrome, allergy\u002Fsensitivity to pregabalin or dexmedetomidine, severe bradycardia (heart rate \\\u003C50 beat per minute), second-degree or above atrioventricular block without pacemaker; severe hepatic or renal insufficiency.\n* Previous cardiac or thoracic surgery, known diagnosis of depression or other major psychiatric diseases, cognitive impairment or inability to cooperate with the study, renal insufficiency, and history of substance abuse.","ALL","65 Years",{"count":70,"type":71},70,"ESTIMATED","INTERVENTIONAL",[74],"PHASE4","The aim of this study is to determine the effect of pregabalin versus dexmedetomidine on the treatment and lasting duration of delirium in fast tracking elderly patients after Coronary Artery Bypass Grafting.",[22,77,78,26],"Delirium Treatment","Coronary Artery Bypass Grafting","2025-06-23",{"date":81,"type":82},"2025-06-25","ACTUAL",{"date":84,"type":82},"2022-12-15",{"date":86,"type":71},"2026-05-15",{"name":5,"class":6},1]